Role of lactulose for prophylaxis of hepatic encephalopathy in cirrhotic patients presenting with upper gastrointestinal bleeding
Phase 4
Completed
- Conditions
- Gastrointestinal hemorrhage is a precipitating cause of hepatic encephalopathy in cirrhosis patients. Lactulose is frist line theraphy of hepatic encephalopathy. Can lactulose prevent hepatic encephalhepatic encephalopathylactulosecirrhosisupper gastrointestinal bleedingpreventionprophylaxis
- Registration Number
- TCTR20200526003
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
cirrhotic patients presenting with upper gastrointestinal bleeding who underwent esophagograstroduodenoscopy within 24 hours after symptom presentation.
Exclusion Criteria
1. underlying disease of neurological disease
2. presence of hepatic encephalopathy at the time of admission
3. history of lactulose usage within 6 weeks before
4. severe co-morbidity such as acute kidney injury, active cardiopulmonary disease
5. history of alcohol ingestion within 7 days before
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of hepatic encephalopathy day 5 incidence of hepatic encepalopathy according to west haven criteria grade 3 or more
- Secondary Outcome Measures
Name Time Method ength of hospitalization form admission to discharge days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie lactulose's efficacy in preventing hepatic encephalopathy in cirrhotic patients with upper gastrointestinal bleeding?
How does lactulose compare to other osmotic laxatives in preventing hepatic encephalopathy after gastrointestinal bleeding in cirrhosis patients?
Are there specific biomarkers that can predict which cirrhotic patients will benefit most from lactulose prophylaxis after upper gastrointestinal bleeding?
What are the potential adverse events associated with lactulose use in cirrhotic patients with gastrointestinal bleeding and how can they be managed?
What combination therapies involving lactulose are being explored for the prevention of hepatic encephalopathy in cirrhosis patients with gastrointestinal hemorrhage?